Commodore Parent 2022, LLC acquires Convey Health Solutions Holdings, Inc. (2022)

Deal facts

Buyer: Commodore Parent 2022, LLC
Target: Convey Health Solutions Holdings, Inc.
Deal value: Not disclosed
Announced: 20 June 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

7 Oct 2022CompletedClosed
Commodore Parent 2022, LLC completes acquisition of Convey Health Solutions Holdings, Inc.
Introductory Note. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) on June 21, 2022 (the “ Prior Report ”), on June 20, 2022, Convey Health Solutions Holdings, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Commodore Parent 2022, LLC, a Delaware li
Source

OpinionExit Mode editorial

We see a clear signal in the announcement that Commodore Parent 2022, LLC has acquired Convey Health Solutions Holdings, Inc. This transaction, completed after its June 2022 debut, represents a classic going-private move within the US healthcare sector. The deal structure relies entirely on cash consideration, which removes the uncertainty of stock-based valuations and provides immediate liquidity for shareholders. For the SME founder watching from across the Atlantic, this illustrates how a pure cash offer can simplify the exit process when public market volatility creates a disconnect between share price and intrinsic business value.

The shift from public to private ownership often grants management the breathing room needed to execute long-term strategies without quarterly earnings pressure. In the healthcare space, where regulatory compliance and operational complexity are high, this freedom is particularly valuable. We note that while the US antitrust landscape requires scrutiny, the absence of a disclosed value suggests the parties may have navigated initial competition thresholds or structured the deal to avoid triggering deeper CMA-style reviews. The use of a special purpose acquisition vehicle like Commodore Parent 2022, LLC is a standard mechanism to isolate risk and facilitate this transition, ensuring the buyer can operate with agility once the public listing requirements are shed.

This deal underscores that the path to a successful exit does not always require a public listing or a complex stock swap. The decision to go private via a cash buyout allows the new owners to focus on consolidation and efficiency within the broader healthcare ecosystem. It is a reminder that private equity sponsors are increasingly active in acquiring established healthcare platforms to drive operational improvements away from the public eye. The mechanics here are straightforward: a clean cash exit that transfers control completely, avoiding the drag of public reporting and the distraction of shareholder activism.

Our view is that founders should audit their current capital structure to determine if the public market is currently undervaluing their specific operational model. If your business faces high compliance costs or requires multi-year investment cycles that public markets dislike, a private cash buyer may offer a superior path to liquidity. This week, reach out to your M&A advisor to model a hypothetical going-private scenario and compare the net proceeds against your current market capitalisation to see if a private sale makes more sense than staying listed.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More going private deals More from Commodore Parent 2022, LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history